Business Description
Nektar Therapeutics
NAICS : 325412
SIC : 2834
ISIN : US6402683063
Share Class Description:
NKTR: Ordinary SharesTotal Employee Number:
63Compare
Compare
Traded in other countries / regions
NKTR.USA0UNL.UKITH0.GermanyNKTR.Mexico Index Membership
S&P 500Russell 3000Russell 2000Russell 2000Russell 3000 IPO Date
1994-05-03Description
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.71 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.65 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.24 | |||||
Beneish M-Score | 3.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -23.7 | |||||
3-Year EBITDA Growth Rate | 33.5 | |||||
3-Year EPS without NRI Growth Rate | 26.4 | |||||
3-Year FCF Growth Rate | 20.7 | |||||
3-Year Book Growth Rate | -46.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -13.67 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.88 | |||||
9-Day RSI | 44.13 | |||||
14-Day RSI | 48.76 | |||||
3-1 Month Momentum % | 8.86 | |||||
6-1 Month Momentum % | 2.59 | |||||
12-1 Month Momentum % | 141.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.42 | |||||
Quick Ratio | 10.42 | |||||
Cash Ratio | 9.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.5 | |||||
Shareholder Yield % | -35.26 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -239.32 | |||||
Net Margin % | -287.84 | |||||
EBITDA Margin % | -222.49 | |||||
FCF Margin % | -428.72 | |||||
OCF Margin % | -428.27 | |||||
ROE % | -48.2 | |||||
ROA % | -29.67 | |||||
ROIC % | -90.08 | |||||
3-Year ROIIC % | -70.56 | |||||
ROC (Joel Greenblatt) % | -1533.78 | |||||
ROCE % | -26.24 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 29.74 | |||||
PB Ratio | 2.74 | |||||
Price-to-Tangible-Book | 2.74 | |||||
EV-to-EBIT | -15.32 | |||||
EV-to-EBITDA | -15.4 | |||||
EV-to-Revenue | 34.27 | |||||
EV-to-Forward-Revenue | 45.08 | |||||
EV-to-FCF | -7.99 | |||||
Price-to-GF-Value | 12.91 | |||||
Price-to-Median-PS-Value | 2.71 | |||||
| Price-to-Net-Current-Asset-Value | 4.52 | |||||
| Price-to-Net-Cash | 5.03 | |||||
Earnings Yield (Greenblatt) % | -6.53 | |||||
FCF Yield % | -9.45 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NKTR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nektar Therapeutics Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 54.589 | ||
| EPS (TTM) ($) | -2.96 | ||
| Beta | 1.528 | ||
| 3-Year Sharpe Ratio | 1 | ||
| 3-Year Sortino Ratio | 3.28 | ||
| Volatility % | 133.75 | ||
| 14-Day RSI | 48.76 | ||
| 14-Day ATR ($) | 3.044114 | ||
| 20-Day SMA ($) | 74.106375 | ||
| 12-1 Month Momentum % | 141.21 | ||
| 52-Week Range ($) | 27.87 - 109 | ||
| Shares Outstanding (Mil) | 34.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nektar Therapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nektar Therapeutics Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 70 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 17:00 | 76.03 (+0.05%) | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 76.03 (+0.05%) | ||
| General meeting for 2026 | 2026-06-04 14:00 | 59.23 (+1.23%) | ||
| Guidance call for 2026 | 2026-06-03 13:20 | 58.56 (-6.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:00 | 85.09 (+0.11%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 85.09 (+0.11%) | ||
| Analyst and Investor Event with Alopecia Areata Experts | 2026-04-20 08:00 | 84.86 (-0.16%) | ||
| Annual report for 2025 | 2026-03-13 | 70.36 (-2.94%) |
Show
Entries
Nektar Therapeutics Frequently Asked Questions
What is Nektar Therapeutics(NKTR)'s stock price today?
The current price of NKTR is $72.54. The 52 week high of NKTR is $109.00 and 52 week low is $27.87.
When is next earnings date of Nektar Therapeutics(NKTR)?
The next earnings date of Nektar Therapeutics(NKTR) is 2026-11-06 Est..
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Nektar Therapeutics(NKTR) does not pay dividend.
Guru Commentaries on NAS:NKTR
Cedar Grove Capital Management
Bullish
2026 Q2
Q226 CGCM Quarterly Letter
What the manager wrote
Nektar reported positive alopecia-areata data in April, providing additional validation that rezpegaldesleukin (rezpeg) may have utility in a second indication. The shares rose approximately 50% following the announcement but subsequently retraced to near our original cost basis. Although the market has not sustained its initial reaction, the data broadened the program’s potential opportunity and strengthened our long-term thesis. We remain patient as the program advances.
Cedar Grove Capital Management
Bullish
2026 Q1
Q126 CGCM Quarterly Letter
What the manager wrote
Nektar Therapeutics (NKTR) is positioned to capitalize on the large atopic dermatitis (AD) market, which has over 80 million patients globally and generates more than $50 billion in sales. Their drug asset, rezpegaldesleukin ('Rezpeg'), has demonstrated competitive efficacy with a clean safety profile and strong durability in maintenance data. If positive data emerges from its Phase 3 trial, peak sales could reach between $3 to $5 billion, significantly outpacing its current enterprise value of approximately $2 billion. The ideal outcome would be a buyout, with commercialization as a secondary option.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers